+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

RUNX1 RARE Grant Program

Alex's Lemonade Stand

The RARE Grant is a two-year award designed to fund research that will lead to the development of therapies for patients with RUNX1-FPD that will either intercept the transition from a precancer state (clonal hematopoiesis) to MDS/AML or prevent blood cancer (before clonal hematopoiesis).

The RUNX1 Research Program hosts an annual scientific conference and patient meeting that brings together grant recipients and other scientists. Grant recipients are expected to present their progress as part of the annual review.

A RARE Grant is $250,000 over 2 years (maximum $125,000 per year may be requested

Application Timeline and Review

• A full proposal must be submitted that meets all guideline criteria as well as all eligibility criteria; otherwise, applications will be administratively rejected.

• Proposals will be reviewed by an independent panel of experts according to the NIH recognized peerreview process.

• Selection criteria include the following:

o Training/Education record o Publication record

o Grant awards and research awards/recognition

o Quality and overall ranking of research proposal based on the NIH 9-point scoring system

o Evidence of collaboration within project proposal - An important sub-goal is to stimulate research progress through collaborations between research groups

o Alignment to overall goal of preventing hematologic malignancies in RUNX1-FPD and the feasibility of translating findings into the clinic

AI Based Application Success Predictor

Predictor	Why It Matters	Supporting Evidence / Patterns
Strong alignment with pediatric oncology	Proposals must clearly address childhood cancers, not adult oncology or general biology.	ALSF emphasizes direct relevance to pediatric disease mechanisms or therapies.
Innovative and translational focus	ALSF favors novel ideas that can move rapidly toward clinical application.	Funded “Innovation” and “A Award” projects often introduce new targets, models, or technologies.
Strong preliminary data	Competitive proposals show feasibility through compelling early data or proof-of-concept experiments.	Peer review guidelines state “preliminary evidence of viability” is key for A and Reach awards.
Track record and mentorship (for early-career applicants)	Demonstrated productivity and strong mentorship plans are major success factors for early investigators.	Past Young Investigator awardees often have >3–5 peer-reviewed publications in pediatric oncology.
Feasibility and scientific rigor	Clear hypothesis, defined aims, and feasible methods are essential.	Reviewers downscore overambitious or poorly justified experimental plans.
Potential for high impact and clinical translation	ALSF prioritizes projects that could change outcomes for children—novel targets, biomarkers, or therapies.	Translational relevance is emphasized in all review criteria.
Institutional and resource support	Strong letters of commitment, lab environment, and access to patient samples or models improve credibility.	Especially important for Reach and Clinical Research Grants.
Collaboration and data sharing	ALSF encourages collaborative teams and open data policies.	“Crazy 8” awards explicitly require cross-institutional collaboration.

⚠️ Common Weaknesses in Unsuccessful Applications

Vague or weak connection to pediatric cancer relevance

Lack of preliminary data to support feasibility

Generic career development plans or weak mentorship (for early-career awards)

Overly technical or unfocused proposals without clear rationale

Insufficient detail on translational pathway (how findings reach clinic)

📊 Funding & Success Rate Insights

Young Investigator Awards: ~10–15 funded annually (success rate ≈15–20%)

A Awards: 5–8 awarded per year; highly competitive (~10% success)

Innovation Grants: <10–15% success rate depending on cycle

Crazy 8 Initiative: Large multi-million-dollar collaborative projects — selected from international competition

✅ Summary: Strongest Predictors

High relevance to pediatric cancer

Novel and translational science

Strong mentorship and career plan (early-career)

Preliminary data demonstrating feasibility

Potential for clinical impact and collaboration

Specialties

Cancer

Oncology

Eligibility Requirements

• Applicant institutions may be based in the U.S. or outside of the U.S. Applicants need not be United States citizens. Funds must be granted to non-profit institutions or organizations.

• Applicants must have an MD, PhD, or MD/PhD (DO, MBBS or equivalent)

• Applicants may have research grants from other funding sources during the award period, but there must be clear documentation of mechanisms to avoid scientific and budgetary overlap.

• Applicants must have research experience working in, and a deep understanding of, normal or malignant hematopoiesis and/or immunology.

Sponsor Details

Sponsor Institute/Organizations: Alex's Lemonade Stand

Sponsor Type: Corporate/Non-Profit

Address: 333 E. Lancaster Ave, #414, Wynnewood, PA 19096 USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity